Armata Pharmaceuticals, Inc. (ARMP) Stock Score, Valuation & Financial Research
Armata Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 10/100.
Quick answer for ARMP
Armata Pharmaceuticals, Inc. currently has a Wall Street Score of 10/100. The stored market price is $4.07. Its financial score is 10/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Armata Pharmaceuticals, Inc. does
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
ARMP financial snapshot
- Wall Street Score:
- 10/100
- Current price:
- $4.07
- Market capitalization:
- $149.4M
- Revenue:
- $3.3M
- Net income:
- $-192.2M
- Free cash flow:
- $-26.3M
- Cash:
- $24.0M
- Total debt:
- $314.0M
- EPS:
- -5.30
- Financial score:
- 10/100
- Valuation score:
- 0/100
- Revenue score:
- 3/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $-26.3M, showing cash burn in the current stored period.
- The balance sheet shows $24.0M of cash versus $314.0M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 10/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ARMP
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.